Samsara BioCapital’s Kalaris Therapeutics KLRS Stock Holding History

Samsara BioCapital’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$74.7M	Hold	12,948,081	–	–	7.26%	5
2025 Q4	$109M	Buy	12,948,081 +1,500,000	+13%	+$9.59M	11.27%	3
2025 Q3	$66.2M	Hold	11,448,081	–	–	8.64%	3
2025 Q2	$30.6M	Hold	11,448,081	–	–	6.25%	4
2025 Q1	$91.9M	Buy	11,448,081 +11,444,501	+319,679%	+$112M	16.39%	2
2024 Q4	$34.6K	Hold	3,580	–	–	﹤0.01%	41
2024 Q3	$66.6K	Hold	3,580	–	–	0.01%	40
2024 Q2	$59.6K	Hold	3,580	–	–	0.01%	38
2024 Q1	$62.2K	Hold	3,580	–	–	0.01%	37
2023 Q4	$56K	Hold	3,580	–	–	0.01%	39
2023 Q3	$177K	Hold	3,580	–	–	0.05%	38
2023 Q2	$280K	Hold	3,580	–	–	0.05%	41
2023 Q1	$324K	Hold	3,580	–	–	0.07%	45
2022 Q4	$422K	Hold	3,580	–	–	0.09%	44
2022 Q3	$650K	Hold	3,580	–	–	0.15%	44
2022 Q2	$321K	Hold	3,580	–	–	0.09%	51
2022 Q1	$556K	Hold	3,580	–	–	0.14%	54
2021 Q4	$1.06M	Hold	3,580	–	–	0.21%	42
2021 Q3	$2.06M	Hold	3,580	–	–	0.32%	39
2021 Q2	$1.63M	Hold	3,580	–	–	0.2%	46
2021 Q1	$1.93M	Hold	3,580	–	–	0.36%	40
2020 Q4	$3.17K	Sell	3,580 -379	-10%	-$292K	0.32%	31
2020 Q3	$2.5M	Buy	+3,959	New	+$2.7M	0.7%	24

Other funds holding KLRS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Samsara BioCapital's KLRS Position: Q1 2026 in Review

Samsara BioCapital held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 12,948,081 shares worth $74.7M. The position accounts for 7.26% of the portfolio, ranked #5.

Samsara BioCapital first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $109M in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

Samsara BioCapital held 12,948,081 shares of Kalaris Therapeutics worth $74.7M as of Q1 2026.
Samsara BioCapital left its Kalaris Therapeutics share count unchanged in Q1 2026.
Kalaris Therapeutics made up 7.26% of Samsara BioCapital's portfolio in Q1 2026, its #5 holding.
Samsara BioCapital first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
Samsara BioCapital's Kalaris Therapeutics position peaked at $109M in Q4 2025.
58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.